Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ó¹æ ÀûÁ¤¼º '°³¼±' ÀÌ»ó¹ÝÀÀ ¹ß»ý·ü '°¨¼Ò'
³»   ¿ë

ó¹æ ÀûÁ¤¼º '°³¼±' ÀÌ»ó¹ÝÀÀ ¹ß»ý·ü '°¨¼Ò'

Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ÇöȲ ¹× ¿î¿µ ¹æ¾È <4>


º» °í¿¡¼­´Â Áö³­ 2020³â 2¿ù ¹ß°£µÈ ¡®ÀǾàǰÁ¤Ã¥¿¬±¸¡¯ 14±Ç 2È£ [³í´Ü] ¿¡ ½Ç·È´ø <Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ÇöȲ ¹× ¿î¿µ ¹æ¾È> ¿ø°í¸¦ ¿øÀúÀÚÀÇ ½ÂÀÎÀ» ¹Þ¾Æ, ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ® ÇмúÁö¸éÀ» ÅëÇØ Àç¼Ò°³ÇϰíÀÚ ÇÑ´Ù. ¡®ÀǾàǰÁ¤Ã¥¿¬±¸¡¯´Â ÀǾàǰ °³¹ß, »ý»ê, À¯Åë ¹× »ç¿ë°ú °ü·ÃµÈ Á¤Ã¥Àû À̽´¸¦ ±íÀÌ ÀÖ°Ô ¿¬±¸, ºÐ¼®ÇØ ÇÕ¸®ÀûÀΠÁ¤Ã¥À» Á¦½ÃÇϰíÀÚ 2006³â Ã¢°£µÈ ÀÌ·¡ ¿¬ 2ȸ ²ÙÁØÈ÷ ¹ßÇàµÇ°í Àִ Á¤±â°£Ç๰ÀÌ´Ù. [ÆíÁýÀÚ ÁÖ]


<Áö³­È£¿¡ À̾>
¥±. º»·Ð
5. ±¹³» Ç×»ýÁ¦ ÀûÁ¤ »ç¿ë ¿©ºÎ¿¡ ´ëÇÑ Æò°¡
(1) ÁúÀû Æò°¡
±¹³» Ç×»ýÁ¦ ÀûÁ¤ »ç¿ë ¿©ºÎ¿¡ ´ëÇÑ Æò°¡´Â 2000³â ÀǾàºÐ¾÷ µµÀÔÀ¸·Î Ç×»ýÁ¦¸¦ Æ÷ÇÔÇÑ ¾àÁ¦±Þ¿© ÀûÁ¤¼º Æò°¡ ½ÃÀÛ, 2006³â ±Þ¼º »ó±âµµ °¨¿° Ç×»ýÁ¦ Ã³¹æ·ü °ø°³, 2007³â ÀÇ·á±â°ü Æò°¡Ç׸ñÀ¸·Î ¼ö¼ú ÀüÈÄ ¿¹¹æÀû Ç×»ýÁ¦ »ç¿ë ÀûÁ¤¼º Æò°¡ µµÀÔ µîÀÌ´Ù.

ÀÌ·¯ÇÑ Á¤Ã¥µé·Î Áö³­ 10¿©³â°£ Ç×»ýÁ¦ »ç¿ë¿¡ ¸¹Àº º¯È­°¡ ÀÖ¾úÀ¸³ª, ¿©ÀüÈ÷ ±¤¹üÀ§ Ç×»ýÁ¦ »ç¿ë·®Àº ²ÙÁØÈ÷ Áõ°¡Çϴ µî ÀÇ·á±â°ü¿¡¼­ Ã³¹æÇϴ Ç×»ýÁ¦ »ç¿ë·®°ú ÀûÀý¼º ÇöȲÀ» ÆÄ¾ÇÇϴ °ÍÀº ¸Å¿ì Áß¿äÇÏ°í ½Ã±ÞÇÑ Çö¾ÈÀÌ´Ù.

2018³â ´ëÇѰ¨¿°ÇÐȸ¿Í ´ëÇÑÈ­Çпä¹ýÇÐȸ¿¡¼­´Â Ç×»ýÁ¦°¡ ÈçÈ÷ Ã³¹æµÇ´Â °¨¿°ÁõÈıº°ú ´Ùºóµµ Ã³¹æ Ç×»ýÁ¦ÀÇ Á¾·ù¸¦ ÆÄ¾ÇÇ졒ʼÎÀûÀýÇÑ Ç×»ýÁ¦ »ç¿ëÀ» ÁÙÀ̱â À§ÇØ Àü¹®°¡ À§¿øÈ¸¸¦ ±¸¼ºÇß´Ù.

¿©±â¿¡¼­´Â Áö±Ý±îÁö ¹ßÇ¥µÈ ±¹³» Ç×»ýÁ¦ »ç¿ëÁöħ µî¿¡ ±Ù°ÅÇÑ Æò°¡Áöħ°ú Ç¥ÁØÁöÇ¥¸¦ °³¹ßÇϰí 20¿©°³ÀÇ ÀÚ¹ßÀû Âü¿©±â°üÀ» ¸ðÁýÇÑ ´ÙÀ½ ÇϷ縦 Á¤ÇØ Ç×»ýÁ¦ »ç¿ë½ÇÅ¿͠ÀûÀý¼ºÀ» Æò°¡Çß´Ù.

ÀÌ Æò°¡¿¡¼­´Â 2018³â 8¿ù 29ÀÏ ½ÃÁ¡¿¡ Ã³¹æµÈ ¸ðµç Ç×»ýÁ¦ Ã³¹æ °ÇÀ» °¨¿° Àü¹®°¡°¡ Á÷Á¢ Àǹ« ±â·Ï°ú °Ë»ç ±â·ÏÀ» °ËÅäÇØ Ç×»ýÁ¦ Ã³¹æ ¸ñÀû ¹× °¨¿° Áúȯ¸íÀ» È®ÀÎÇϰí ÁúÀû Æò°¡¸¦ ÁøÇàÇß´Ù. 

Àüü Ç×»ýÁ¦ Ã³¹æ°Ç 1¸¸ 948°Ç(Ä¡·áÀû Ç×»ýÁ¦ 7999°Ç, ³»°úÀû ¿¹¹æ Ç×»ýÁ¦ 844°Ç, ¼ö¼úÀÇ ¿¹¹æÀû Ç×»ýÁ¦ 2105°Ç)¿¡ ´ëÇÑ Ç×»ýÁ¦ Ã³¹æ ÀûÀý¼º Æò°¡¸¦ ÁøÇàÇÑ °á°ú 27.7%ÀÇ Ç×»ýÁ¦ Ã³¹æ ºÎÀûÇÕÀ²À» È®ÀÎÇß´Ù. 

ÀÌ ¿¬±¸ °á°ú¸¦ ¹ÙÅÁÀ¸·Î Ç×»ýÁ¦ Ã³¹æ ÀûÀý¼º °ü¸®¸¦ À§ÇÑ ±¸Ã¼ÀûÀ̰í, Àå±âÀûÀΠ°èȹÀ» ±¹°¡Àû Â÷¿ø¿¡¼­ ¹Ýµå½Ã ¸¶·ÃÇØ¾ß ÇϰڴÙ.

(2) ¾çÀû Æò°¡
º¸°Çº¹ÁöºÎ¡¤°Ç°­º¸Çè½É»çÆò°¡¿ø¿¡ µû¸£¸é ±¹³» Ç×»ýÁ¦ »ç¿ë·®Àº 2016³â ±âÁØ 34.8 DDD(Defined Daily Dose)/Àα¸ 1000¸í/ÀÏ(DDD per 1000 inhabitants per day, ÀÌÇÏ DID)·Î, °æÁ¦Çù·Â°³¹ß±â±¸(OECD) ¼Ò¼Ó ±¹°¡ Æò±ÕÀΠ21.1 DIDº¸´Ù ³ôÀº °ÍÀ¸·Î Á¶»çµÆ´Ù. 

±¹³» Ç×»ýÁ¦ ÃѠ󹿷®Àº 2002³â ÇÏ·ç 1000¸í´ç 15.9 DID¿¡¼­ 2013³â 24.2 DID ¿´°í, ÀÌÈÄ ²ÙÁØÈ÷ Áõ°¡Çß´Ù. 

±¹³» Ç×»ýÁ¦ »ç¿ëÀڷḦ °è¿­º°·Î ºÐ¼®ÇØ º¸°íÇÑ ¿¬±¸¿¡ ÀÇÇϸé, Æä´Ï½Ç¸° °è¿­Àº Ç×»ýÁ¦ »ç¿ë·®ÀÌ °¨¼ÒÇϴ ¹Ý¸é, 3¼¼´ë ¼¼ÆÄ°è, ¸¶Å©·Î¶óÀ̵堰迭ÀÇ Ç×»ýÁ¦´Â Áö¼ÓÀûÀ¸·Î »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ¾ú´Ù. 

±¤¹üÀ§ Ç×»ýÁ¦¿Í ³»¼º±Õ¿¡ À¯È¿ÇÑ Ç×»ýÁ¦¿¡ ´ëÇØ¼­ ¿¬µµº° »ç¿ë¾ç»óÀ» »ìÆìº» °á°ú ±¤¹üÀ§ Ç×»ýÁ¦´Â 2011³â 8.1 DID ¿¡¼­ 2015³â 8.6 DID·Î Á¡Â÷ Áõ°¡ÇÏ°í ³»¼º±Õ¿¡ À¯È¿ÇÑ Ç×»ýÁ¦´Â 2011³â ´ëºñ 2015³â¿¡ 1.5¹è Áõ°¡Çϴ °ÍÀ¸·Î º¸°íµÆ´Ù.

À̸¦ ÅëÇØ ±¤¹üÀ§ Ç×»ýÁ¦ÀÇ »ç¿ëÀÇ ÀûÁ¤ °ü¸®°¡ ÇÊ¿äÇÔÀ» È®ÀÎÇß´Ù.

(3) ±¹³» Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ µµÀÔ ¼º°ú
´ÙÇÐÁ¦ÀûÀΠÇ×»ýÁ¦ °ü¸®ÆÀÀ» ¿î¿µÁßÀΠ±¹³» 1°³ »ó±ÞÁ¾ÇÕº´¿ø¿¡¼­, Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ µµÀÔ¿¡ µû¸¥ Ç×Çø±â¼º Áߺ¹ ¹× Ç×»ýÁ¦ °æ±¸Á¦·ÎÀÇ Àüȯ µî Ç×»ýÁ¦ »ç¿ë ÀûÁ¤¼º °³¼± ¹× À¯ÀÇÇÑ Àç¿ø±â°£ °¨¼Ò ¹× Ç×»ýÁ¦ ºñ¿ë °¨¼Ò¸¦ º¸°íÇÑ ¹Ù ÀÖ´Ù.

Ç×»ýÁ¦ °ü¸® ¾à»çÀÇ Ç×»ýÁ¦ Ã³¹æÁßÀç È°µ¿À¸·Î ÀÎÇØ 3°³¿ù°£ ¾à 630¸¸¿øÀÇ ÀÇ·áºñ °¨¼ÒÇßÀ¸¸ç ºÎÀûÀý Ã³¹æ ºñÀ²Àº 23.8%¿¡¼­ 9.7%·Î °¨¼ÒÇß´Ù.

¶ÇÇÑ ÀÇ»ç¿Í ¾à»ç·Î ±¸¼ºµÈ Ç×»ýÁ¦ °ü¸®ÆÀ ÁßÀç ÇÁ·Î±×·¥ ¸ðµ¨ Ã¢ÃâÀ» ÅëÇÑ ÁßÀç ÀÌÈÄ ºÒÇÊ¿äÇÑ Ç×Çø±â Ç×»ýÁ¦¸¦ º´¿ëÇϴ »ç·Ê°¡ °¨¼ÒÇß´Ù. 

Áï ÁßÀç ½ÃÇà ÀÌÈÄ ÁßÀç Àü¿¡ ºñÇØ ºÒÇÊ¿äÇÑ Ç×Çø±â Ç×»ýÁ¦ º´¿ë°Ç¼ö 73.9% °¨¼ÒÇß°í, 3ÀÏ ÀÌ»ó Åõ¿©Çϴ °Ç¼ö 67.8% °¨¼ÒÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

5°³ »ó±ÞÁ¾ÇÕº´¿ø¿¡¼­ 2017³â ÀڷḦ ±âÁØÀ¸·Î, ÀÔ¿ø È¯ÀÚ ´ë»ó Ç×»ýÁ¦ »ç¿ë ¹× ºÎÀۿ령߻ý·ü ºÐ¼® °á°ú¿¡¼­µµ, Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ½ÃÇàÀ» ÇÑ º´¿ø¿¡¼­´Â ±×·¸Áö ¾ÊÀº º´¿ø¿¡ ºñÇØ Ã³¹æ ÀûÁ¤¼º °³¼± ¹× ÀÌ»ó¹ÝÀÀ ¹ß»ý·ü °¨¼ÒµÊÀ» È®ÀÎÇß´Ù. 

¶ÇÇÑ Ç×»ýÁ¦ Ã³¹æ °ËÅä¿¡ µû¸¥ ÁßÀç´Â Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥À» ½ÃÇàÇϴ º´¿ø¿¡¼­ ³ô°Ô °üÂûµÆ´Ù.<´ÙÀ½È£¿¡ °è¼Ó>


[±â»çÃâó] https://www.kpanews.co.kr/academy/show.asp?page=1&search_cate=8&idx=519

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
99 [´ëÇѾà»çÀú³Î] ó¹æ ÀûÁ¤¼º '°³¼±' ÀÌ»ó¹ÝÀÀ ¹ß»ý·ü '°¨¼Ò' ÀÌÁö¿¬ 2021-02-23 18
98 [´ëÇѾà»çÀú³Î] ÇØ¿Ü 85% º´¿ø, Ç×»ýÁ¦ »ç¿ë ¸ð´ÏÅ͸µ ½Ç½Ã ÀÌÁö¿¬ 2021-02-16 30
97 [´ëÇѾà»çÀú³Î] °¨¿°Àü¹®¾à»ç ÇÁ·Î±×·¥ ¼±µÎ¡¦ÀÇ·áÁø°ú ÆÀÀÇ·á ÀÌÁö¿¬ 2021-02-10 42
96 [¾à»ç°ø·Ð]´ÙÁ¦¾à¹° ÃÊÁ¡, 'Çѱ¹Çü Åð¿øÄɾºñ½º' ±¹Á¦¹«´ë¼­ 'ÁÖ¸ñ' ±è¼±Èñ 2021-02-04 57
95 [¸Þµð°ÔÀÌÆ®]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, FIP¿¡ Çѱ¹ Åð¿øÄɾºñ½º ¼Ò°³ ±è¼±Èñ 2021-02-04 54
94 [´ëÇѾà»çÀú³Î] Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ÇöȲ ¹× ¿î¿µ ¹æ¾È ÀÌÁö¿¬ 2021-02-02 48
93 [´ëÇѾà»çÀú³Î] ȯÀÚ 'Æ÷°ýÀû ¾à¹° »ç¿ë °ü¸®' ÁÖ¿ä °ú¾÷ ÀÌÁö¿¬ 2021-01-26 64
92 [¸ÞµðÆÄ³ª´º½º]'Äڷγª19 ´ëÀÀ¡¤ÅëÇÕµ¹º½' ´Ù·é ÀǾàǰÁ¤Ã¥¿¬±¸ ¹ß°£ ±è¼±Èñ 2021-01-19 89
91 [¾à»ç°ø·Ð] ¾à±¹ °ÅÁ¡ Àڻ쿹¹æ»ç¾÷, »ý¸íÁöÅ´ÀÌ ¿ªÇÒ 'ÅåÅå' ±è¼±Èñ 2021-01-19 93
90 [µ¥Àϸ®ÆÊ] ÀϺ»¾à±¹ÀÇ ÁøÈ­¡¦Ä«µå·Î 'Áߺ¹Åõ¾à¡¤³²Àº ¾à °ü¸®±îÁö' ±è¼±Èñ 2021-01-19 86
89 [´ëÇѾà»çÀú³Î] ¼¼ÀÌÇÁ¾à±¹¡¤¹æ¹®¾à·á µî Ȱµ¿ Áö¼Ó Áõ°¡ ÀÌÁö¿¬ 2021-01-19 62
88 [´ëÇѾà»çÀú³Î] ¾à±¹ ó¹æÁýÁßµµ º¯È­¿Í ¾à±¹¾à»çÀÇ »çȸÀû ¿ªÇÒ Ãß±¸ ÀÌÁö¿¬ 2021-01-13 101
87 [´ëÇѾà»çÀú³Î] ÀåÁ¡Àº Ű¿ì°í ´ÜÁ¡Àº ¾ø¾Ö´Â ±³À°¹æ¹ýÀº? ÀÌÁö¿¬ 2021-01-06 134
86 [´ëÇѾà»çÀú³Î] 'Àڱ⠹ݿµ ¾ç½Ä' ÅëÇØ ¾à±¹ Àü¹®°¡ ±âÁØ ÆÄ¾Ç ÀÌÁö¿¬ 2020-12-29 136
85 [´ëÇѾà»çÀú³Î] CPD °³³ä µîÀå 80³â, ¿ì¸®³ª¶ó´Â ¾ÆÁ÷¡¦ ÀÌÁö¿¬ 2020-12-22 145

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»